What do systematic reviews say?

Anti‐EGFR therapy vs placebo or usual care

Anti‐EGFR therapy showed no clear difference in lymphopenia compared with placebo or standard of care (low certainty).

• Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
  OR 0.97 [0.19, 4.81]
  4 studies · 1146 participants
  Low

Anti‐EGFR therapy vs placebo or usual care

Anti‐EGFR therapy showed no clear difference in neutropenia compared with placebo or standard of care (low certainty).

• Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
  OR 1.29 [0.82, 2.03]
  4 studies · 1146 participants
  Low

Anti‐EGFR therapy vs placebo or usual care

Anti‐EGFR therapy showed no clear difference in thrombocytopenia compared with placebo or standard of care (low certainty).

• Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
  OR 3.69 [0.51, 26.51]
  4 studies · 1146 participants
  Low

Anti‐EGFR therapy vs placebo or usual care

Anti‐EGFR therapy showed no clear difference in progression‐free survival ‐ first‐line studies compared with placebo or standard of care (low certainty).

• Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
  HR 0.94 [0.81, 1.1]
  2 studies · 894 participants
  Low

Anti‐EGFR therapy vs placebo or usual care

Anti‐EGFR therapy may leads to lower progression‐free survival ‐ recurrent disease studies compared with placebo or standard of care (low certainty).

• Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
  HR 0.75 [0.58, 0.96]
  3 studies · 275 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 81 participants
  GRADE not reported

Intervention not reported

The intervention showed no clear difference in TMZ (3 RCTs, 538 participants) (low certainty).

• Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis 2020 · Cochrane Headline outcomes only
  HR 0.95 [0.71, 1.26]
  3 studies · 538 participants
  Low

Intervention not reported

The intervention leads to lower CRT (2 RCTs; 635 participants) (high certainty).

• Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis 2020 · Cochrane Headline outcomes only
  HR 0.67 [0.56, 0.8]
  2 studies · 635 participants
  High

Intervention not reported

The intervention probably leads to lower BEV_CRT (1 RCT; 73 participants) (moderate certainty).

• Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis 2020 · Cochrane Headline outcomes only
  HR 0.56 [0.31, 0.99]
  1 study · 73 participants
  Moderate

Intervention not reported

• Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 60 participants
  GRADE not reported

Intervention not reported

The intervention showed no clear difference in RT 40 (4 RCTs; 930 participants) (low certainty).

• Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis 2020 · Cochrane Headline outcomes only
  HR 0.94 [0.72, 1.23]
  4 studies · 40 participants
  Low

Intervention not reported

It is very uncertain whether the intervention changes BEV_RT (1 RCT; 75 participants) (very low certainty).

• Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis 2020 · Cochrane Headline outcomes only
  HR 1.01 [0.58, 1.79]
  1 study · 75 participants
  Very low

Intervention not reported

It is very uncertain whether the intervention changes TMZ (3 RCTs, 538 participants) (very low certainty).

• Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis 2020 · Cochrane Headline outcomes only
  HR 0.89 [0.71, 1.11]
  3 studies · 538 participants
  Very low

Intervention not reported

The intervention may leads to lower CRT (2 RCTs; 635 participants) (low certainty).

• Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis 2020 · Cochrane Headline outcomes only
  HR 0.63 [0.46, 0.87]
  2 studies · 635 participants
  Low